Medicare is staring down tens of billions of dollars in future expenses if it begins covering obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, and the Congressional Budget Office has suggested that may be soon, thanks to the heart benefits seen in patients taking Wegovy.
In written questions, Rep. Buddy Carter (R-GA) asked the CBO how it is considering the costs of GLP-1s like Wegovy and Zepbound now that the FDA expanded the label for Novo’s drug to include cardiovascular risk reduction benefits.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.